We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

89 hedge funds and large institutions have $226M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

947% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $120K

233% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 9

75% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 16

62% more capital invested

Capital invested by funds: $140M → $226M (+$86.5M)

31% more funds holding

Funds holding: 68 → 89 (+21)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
89
Holders Change
+21
Holders Change %
+30.88%
% of All Funds
1.43%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
30
Increased
28
Reduced
16
Closed
9
Calls
$1.26M
Puts
$120K
Net Calls
+$1.14M
Net Calls Change
+$992K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.83M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.64M
3
Marshall Wace
Marshall Wace
United Kingdom
+$2.34M
4
PBA
Paradigm Biocapital Advisors
New York
+$1.67M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$3.2M
2
PA
Perceptive Advisors
New York
-$2.65M
3
SCM
Silverarc Capital Management
Massachusetts
-$1.48M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.44M
5
SFM
Sphera Funds Management
Israel
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$68.3M +$1.57M +343,355 +3%
PCM
2
Pentwater Capital Management
Florida
$31.7M – – –
EC
3
EcoR1 Capital
California
$14M – – –
PBA
4
Paradigm Biocapital Advisors
New York
$12.9M +$1.67M +364,708 +18%
Vanguard Group
5
Vanguard Group
Pennsylvania
$12.4M -$245K -53,560 -2%
SCM
6
Silverarc Capital Management
Massachusetts
$11.8M -$1.48M -324,277 -13%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$9.39M +$2.64M +577,716 +48%
BlackRock
8
BlackRock
New York
$9.11M +$1.24M +271,156 +19%
Millennium Management
9
Millennium Management
New York
$8.73M +$6.83M +1,495,099 +985%
CAM
10
Cormorant Asset Management
Massachusetts
$6.09M -$3.2M -700,000 -38%
ACM
11
Aisling Capital Management
New York
$5.53M – – –
LCM
12
Laurion Capital Management
New York
$2.89M – – –
Marshall Wace
13
Marshall Wace
United Kingdom
$2.71M +$2.34M +511,404 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.6M +$166K +36,420 +8%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$1.8M +$655K +143,237 +73%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$1.62M -$541K -118,428 -23%
Invesco
17
Invesco
Georgia
$1.54M +$1.33M +290,349 New
ASN
18
Advisory Services Network
Georgia
$1.41M +$9.14K +2,000 +0.8%
Charles Schwab
19
Charles Schwab
California
$1.4M +$24.2K +5,286 +2%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$1.31M +$383K +83,675 +51%
EI
21
EAM Investors
California
$1.16M +$998K +218,305 New
HF
22
HRT Financial
New York
$1.06M +$916K +200,351 New
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$1.06M +$912K +199,564 New
Renaissance Technologies
24
Renaissance Technologies
New York
$1.04M -$672K -147,000 -43%
DMKJ
25
David M. Knott Jr
$895K +$80.2K +17,553 +12%
1
2 3 4

PSTX Hedge Fund Activity: Q4 2022 in Review

89 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2022, worth a combined $226M — up 62% from $140M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PSTX positions and 9 closed out — a net gain of 21 holders — while 28 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.83M. The largest seller was Cormorant Asset Management, cutting an estimated $3.2M.

  • 89 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2022, up from 68 in Q3 2022.
  • Funds reported $226M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2022, up 62% quarter-over-quarter.
  • 30 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2022 and 9 closed out, a net change of +21 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $6.83M added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2022 was Cormorant Asset Management, an estimated $3.2M sold.

Based on aggregated 13F filings for Q4 2022.